Addex Therapeutics to Release Q1 2021 Financial Results and Host Conference Call on May 5, 2021
May 03 2021 - 1:00AM
Geneva, Switzerland,
May 3,
2021 – Addex
Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a
clinical-stage pharmaceutical company pioneering allosteric
modulation-based drug discovery and development, today
announced that it will issue its Q1 2021 financial results on
Wednesday May 5, 2021. Tim Dyer, CEO, Roger Mills, CMO and Robert
Lütjens, Head of Discovery Biology will provide a business update
and review its pipeline during a teleconference and webcast for
investors, analysts and the media on Wednesday, May 5, 2021 at
16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT).
Title: Addex
to Announce Q1 2021 Financial
ResultsDate:
May 5,
2021Time:
16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT)
Joining the Conference
Call:1: In the 10 minutes prior to the call start time,
call the appropriate participant dial-in
number. Dial-In Numbers:
-
Switzerland +41
44 580 65 22
-
UK +44
20 30 09 24 70
-
U.S.A +1
87 74 23 08 30
- Other
Countries
2: Provide the Operator with the
Participation Pin Code:
64754025#
Link to live event online:1: In
the 10 minutes prior to the call start time, sign in online by
following this Webex link.2: Password: Welcome
About Addex
Therapeutics:Addex Therapeutics is a
clinical-stage pharmaceutical company focused on the development
and commercialization of an emerging class of novel orally
available small molecule drugs known as allosteric modulators for
neurological disorders. Allosteric modulators offer several
potential advantages over conventional non-allosteric molecules and
may offer an improved therapeutic approach to conventional
"orthosteric" small molecule or biological drugs. Addex’s
allosteric modulator drug discovery platform targets receptors and
other proteins that are recognized as essential for therapeutic
intervention. Addex’s lead product candidate, dipraglurant (mGlu5
negative allosteric modulator or NAM), is poised to start a pivotal
registration clinical trial for Parkinson’s disease levodopa
induced dyskinesia (PD-LID) in Q2 2021. Addex is also investigating
dipraglurant's therapeutic use in blepharospasm (a type of
dystonia), for which a clinical trial is expected to be initiated
in Q2 2021. Addex's third clinical program, ADX71149 (mGlu2
positive allosteric modulator or PAM), developed in collaboration
with Janssen Pharmaceuticals, Inc., is scheduled to enter a phase
2a proof of concept clinical trial for the treatment of epilepsy in
Q2 2021. Addex’s GABAB PAM program has been licensed to Indivior
PLC, which is focused on development for the treatment of
addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7
NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4
PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative
disorders. Addex shares are listed on the SIX Swiss Exchange and
American Depositary Shares representing its shares are listed on
the NASDAQ Capital Market, and trade under the ticker symbol "ADXN"
on each exchange.
Press Contacts:
Tim DyerChief Executive OfficerTelephone: +41 22 884 15
55 PR@addextherapeutics.com |
Mike SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
James
CarbonaraHayden IR+1 (646)-755-7412james@haydenir.com |
Forward Looking Statements:This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended, including in respect of the anticipated
initiation and progress of clinical trials and
preclinical studies, and its future financing activities. The words
“may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release, are based on management's current expectations and
beliefs and are subject to a number
of risks, uncertainties and important factors that may
cause actual events or results to differ materially from those
expressed or implied by any forward-looking statements contained in
this press release, including, without limitation, uncertainties
related to market conditions. These and other risks and
uncertainties are described in the Company’s Annual Report on
Form 20-F filed with the SEC on March 11, 2021, as well as market
conditions and regulatory review.
Any forward-looking statements contained in this
press release represent Addex Therapeutics’ views only as of the
date hereof and should not be relied upon as representing its views
as of any subsequent date. Addex Therapeutics explicitly disclaims
any obligation to update any forward-looking statements, except as
required by law.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Apr 2024 to May 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From May 2023 to May 2024